Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
24.33
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genmab A/S ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Moderna Stock Getting Closer To Key Technical Benchmark
February 10, 2023
On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.
Via
Investor's Business Daily
Anavex Life Sciences Stock Shows Improved Price Strength Rating
February 07, 2023
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75.
Via
Investor's Business Daily
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
January 19, 2023
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.
Via
Investor's Business Daily
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
January 11, 2023
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
3 Biotech Companies to Watch in 2023
January 06, 2023
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.
Via
InvestorPlace
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
December 21, 2022
From
Genmab A/S
Via
Business Wire
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
December 14, 2022
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.
Via
Investor's Business Daily
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
December 11, 2022
From
Genmab A/S
Via
Business Wire
Our 7 Top Biotech Stock Picks for 2023
December 09, 2022
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.
Via
InvestorPlace
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
December 08, 2022
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier.
Via
Investor's Business Daily
3 Hot Stocks That Could Live Up to Their Lofty Valuations
December 08, 2022
These companies have long runways of growth ahead
Via
The Motley Fool
Is AbbVie Stock a Buy Now?
December 06, 2022
The pharmaceutical company prepared well as Humira approaches its patent cliff next year.
Via
The Motley Fool
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
November 29, 2022
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.
Via
Investor's Business Daily
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
November 21, 2022
From
Genmab
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
November 25, 2022
On Friday, 68 companies reached new 52-week highs.
Via
Benzinga
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
November 11, 2022
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84.
Via
Investor's Business Daily
Stocks That Hit 52-Week Lows On Monday
November 21, 2022
During Monday's session, 50 stocks hit new 52-week highs.
Via
Benzinga
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
November 03, 2022
From
Genmab A/S
Via
Business Wire
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
October 28, 2022
From
Genmab A/S
Via
Business Wire
3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink
October 25, 2022
You may have to take a shot on some riskier plays if you want to make up your portfolio's significant loss of yardage.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
October 21, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Kura Oncology Stock Shows Improved Relative Strength; Still Shy Of Benchmark
October 14, 2022
In a welcome move, Kura Oncology stock saw its Relative Strength Rating improve from 69 to 75 on Wednesday.
Via
Investor's Business Daily
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating
October 12, 2022
On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before.
Via
Investor's Business Daily
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength
October 10, 2022
On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93.
Via
Investor's Business Daily
Pacira Pharmaceuticals Stock Shows Rising Relative Strength
October 07, 2022
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73.
Via
Investor's Business Daily
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment
September 27, 2022
Via
Benzinga
Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating
September 23, 2022
Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.
Via
Investor's Business Daily
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
September 14, 2022
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.
Via
Investor's Business Daily
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
September 09, 2022
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.